Crestline Management LP lowered its stake in Kadmon Holdings Inc (NYSE:KDMN) by 6.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 561,040 shares of the company’s stock after selling 39,188 shares during the period. Crestline Management LP owned approximately 0.71% of Kadmon worth $2,031,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in Kadmon in the 2nd quarter valued at about $114,000. Bank of New York Mellon Corp bought a new stake in Kadmon in the 3rd quarter valued at about $119,000. Old West Investment Management LLC bought a new stake in Kadmon in the 3rd quarter valued at about $169,000. Wells Fargo & Company MN boosted its holdings in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock valued at $234,000 after purchasing an additional 8,742 shares during the period. Finally, BlueCrest Capital Management Ltd bought a new stake in Kadmon in the 4th quarter valued at about $241,000. Institutional investors and hedge funds own 61.71% of the company’s stock.
Shares of Kadmon Holdings Inc (KDMN) traded up $0.05 during trading on Wednesday, hitting $4.29. 24,439 shares of the stock were exchanged, compared to its average volume of 1,126,765. Kadmon Holdings Inc has a 12 month low of $2.05 and a 12 month high of $5.86. The company has a market cap of $337.38, a P/E ratio of -2.85 and a beta of 5.59.
A number of research firms have issued reports on KDMN. Zacks Investment Research raised shares of Kadmon from a “strong sell” rating to a “hold” rating in a report on Saturday. Piper Jaffray Companies reissued a “positive” rating and issued a $9.00 price objective (up previously from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a report on Friday, March 9th. Finally, Jefferies Group boosted their price objective on shares of Kadmon to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 13th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $10.21.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/14/crestline-management-lp-decreases-position-in-kadmon-holdings-inc-kdmn.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.